Section 12: Evaluation and Management of Patients with Acute Decompensated Heart Failure

Journal of Cardiac Failure

Volumn 16, Issue 6, 2010, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; INOTROPIC AGENT; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; METOLAZONE; MILRINONE; MORPHINE; NESIRITIDE; NITROPRUSSIDE SODIUM; PIOGLITAZONE; PREGABALIN; PSEUDOEPHEDRINE; ROSIGLITAZONE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VASODILATOR AGENT;

ABDOMINAL DISCOMFORT; ACUTE HEART FAILURE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD VOLUME; CASE MANAGEMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION GARMENT; DEFIBRILLATOR; DISEASE COURSE; DISEASE PREDISPOSITION; DIURETIC ACTIVITY; DIURETIC THERAPY; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; FLUID INTAKE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LUNG EDEMA; MENTAL HEALTH; MUSCLE CRAMP; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DRIVE; RISK ASSESSMENT; SIDE EFFECT; SODIUM RESTRICTION; TACHYCARDIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT PLANNING; ULTRAFILTRATION; VENOUS THROMBOEMBOLISM;

EID: 77953631203     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.05.021     Document Type: Article

References (145)

1. U.S. Department of Health and Human Services. Health Care Finance Organization. MEDPAR Inpatient Hospital Datafile, Fiscal Year 1998 (1999), Bureau of Data Management and Strategy, Washington DC June Update
2. Adams Jr. K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
3. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., and Boscardin W.J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
4. Krumholz H.M., Parent E.M., Tu N., Vaccarino V., Wang Y., Radford M.J., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
5. American Heart Association. Heart disease and stroke statistics-2004 update (2004), American Heart Association, Dallas TX
6. Blackledge H.M., Tomlinson J., and Squire I.B. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 89 (2003) 615-620
7. Felker G.M., Adams Jr. K.F., Konstam M.A., O'Connor C.M., and Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 145 Suppl (2003) S18-S25
8. Baig M.K., Mahon N., McKenna W.J., Caforio A.L., Bonow R.O., Francis G.S., et al. The pathophysiology of advanced heart failure. Am Heart J 135 (1998) S216-S230
9. LeJemtel T.H., and Padeletti J.S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 49 (2007) 171-180
10. Maisel A.S., and McCullough P.A. Cardiac natriuretic peptides:a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med Suppl 4 (2003) S3-12
11. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Due P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
12. Baughman K.L. B-type natriuretic peptide-a window to the heart. N Engl J Med 347 (2002) 158-159
13. Maisel A.S., McCord J., Nowak R.M., Hollander J.E., Wu A.H., Due P., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2010-2017
14. Maisel A.S., Clopton P., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., et al. Impact of age, race, and sex on the ability of B- type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147 107 (2004) 8-84
15. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
16. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
17. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Lianos J., Santalo-Bel M., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
18. Januzzi J.L., chen-Tournoux A.A., and Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 101 (2008) 29-38
19. Forfia P.R., Watkins S.P., Rame J.E., Stewart K.J., and Shapiro E.P. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45 (2005) 1667-1671
20. Kazanegra R., Cheng V., Garcia A., Krishnaswamy P., Gardetto N., Clopton P., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29
21. Cheng V., Kazanagra R., Garcia A., Lenert L., Krishnaswamy P., Gardetto N., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
22. Logeart D., Thabut G., Jourdain P., Chavelas C., Beyne P., Beauvais F., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
23. Gackowski A., Isnard R., Golmard J.L., Pousset F., Carayon A., Montalescot G., et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 25 (2004) 1788-1796
24. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
25. Jourdain P., Jondeau G., Funck F., Gueffet P., Le Helloco A., Donal E., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
26. Pfisterer M., Buser P., Rickli H., Gutmann M., Erne P., Rickenbacher P., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
27. th Annual Scientific Session of the American College of Cardiology, Late Breaking Clinical Trial Session, March 29, 2009.
28. Cowie M.R., Jourdain P., Maisel A., Dahlstrom U., Follath F., Isnard R., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
29. Tang W.H., Girod J.P., Lee M.J., Starling R.C., Young J.B., Van Lente F., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108 (2003) 2964-2966
30. Wu A.H., and Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6 (2004) 355-358
31. Yap L.B., Mukerjee D., Timms P.M., Ashrafian H., and Coghlan J.G. Natriuretic peptides, respiratory disease, and the right heart. Chest 126 (2004) 1330-1336
32. Mark D.B., and Felker G.M. B-type natriuretic peptide-a biomarker for all seasons?. N Engl J Med 350 (2004) 718-720
33. Chaudry S.I., Wang Y., Concato J., Gill T.M., and Krumholz H.M. Patterns of weight change preceding hospitalization for heart failure. Circulation 116 (2007) 1549-1554
34. Heart Failure Executive Committee, Peacock W.F., Fonarow G.C., Heart Failure Diagnosis Subcommittee, Ander D.S., Maisel A., et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Crit Pathw Cardiol 7 (2008) 83-86
35. Storrow A.B., Collins S.P., Lyons M.S., Wagoner L.E., Gibler W.B., and Lindsell C.J. Emergency department observation of heart failure: preliminary analysis of safety and cost. Congest Heart Fail 11 (2005) 68-72
36. Peacock IV W.F., Young J., Collins S., Diercks D., and Emerman C. Heart failure observation units: optimizing care. Ann Emerg Med 47 (2006) 22-33
37. Nohria A., Tsang S.W., Fang J.C., Lewis E.F., Jarcho J.A., Mudge G.H., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 (2003) 1797-1804
38. Gupta S., and Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 26 (2005) 644-649
39. Neuberg G.W., Miller A.B., O'Connor C.M., Belkin R.N., Carson P.E., Cropp A.B., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
40. Gheorghiade M., Gattis W.A., Adams Jr. K.F., Jaffe A.S., and O'Connor C.M. A prospective randomized study of nesiritide versus dobutamine in decompensated heart failure (PRESERVED-HF): Design and preliminary data. J Card Fail 9 (2003) S63
41. Schulz R., Rose J., Martin C., Brodde O.E., and Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 88 (1993) 684-695
42. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
43. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
44. Butler J., Forman D.E., Abraham W.T., Gottlieb S.S., Loh E., Massie B.M., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
45. Gottlieb S.S., Abraham W., Butler J., Forman D.E., Loh E., Massie B.M., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8 (2002) 136-141
46. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
47. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 (2000) 685-693
48. Verma S.P., Silke B., Hussain M., Nelson G.I., Reynolds G.W., Richmond A., et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol 10 (1987) 38-46
49. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., and Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103 (1985) l-6
50. Marenzi G., and Agostoni P. Hemofiltration in heart failure. Int J Artif Organs 27 (2004) 1070-1076
51. Jaski B.E., Ha J., Denys B.G., Lamba S., Trupp R.J., and Abraham W.T. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 9 (2003) 225-231
52. Costanzo M.R., Saltzburg M., O'Sullivan J., and Kotsos T. EUPHORIA trial: Early ultrafiltration therapy in patients with decompensated heart failure and observed resistance to intervention with diuretic agents. J Card Fail 10 Suppl (2004) S78
53. Bart B.A., Boyle A., Bank A.J., Anand I., Olivari M.T., Kraemer M., et al. Randomized controlled trial of ultrafiltration versus usual care for hospitalized patients with heart failure: preliminary report of the Rapid Trial. J Card Fail 10 Suppl (2004) S23
54. Costanzo M.R., Guglin M.E., Saltzberg M.T., Jessup M.L., Bart B.A., Teerlink, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
55. Brater D.C. Diuretic therapy. N Engl J Med 339 (1998) 387-395
56. Stevenson L.W., and Tillisch J.H. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 74 (1986) 1303-1308
57. Francis G.S., Siegel R.M., Goldsmith S.R., et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103 (1985) 1-6
58. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
59. Libetta C., Sepe V., Zucchi M., et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 22 (2007) 2013-2019
60. Guazzi M.D., Agostoni P., Perego B., et al. Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 72 (1994) 534-539
61. Schrier R.W., and Martin P.Y. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 449 (1998) 415-426
62. Channer K.S., McLean K.A., Lawson-Matthew P., and Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71 (1994) 146-150
63. Dormans T.P., van Meyel J.J., Gerlag P.G., Tan Y., Russel F.G., and Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28 (1996) 376-382
64. Koelling T.M., Johnson M.L., Cody R.J., and Aaronson K.D. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 111 (2005) 179-185
65. Klein L., O'Connor C.M., Leimberger J.D., Gattis-Stough W., Pina I.L., Felker G.M., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME- CHF) study. Circulation 111 (2005) 2454-2460
66. Saxon L.A., Stevenson W.G., Middlekauff H.R., Fonarow G., Woo M., Moser D., et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 72 (1993) 62-65
67. Kearney M.T., Fox K.A., Lee A.J., Prescott R.J., Shah A.M., Batin P.D., et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 40 (2002) 1801-1808
68. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
69. Gheorghiade M., Abraham W.T., Albert N.M., Gattis Stough W., Greenberg B.H., O'Connor C.M., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 28 (2007) 980-988
70. Renneboog B., Musch W., Vandemergel X., Manto M.U., and Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119 (2006) 71.e1-78
71. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., and Orlandi C. SALT Investigators.Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
72. Ghali J.K., Koren M.J., Taylor J.R., Brooks-Asplund E., Fan K., and Long W.A. Smith Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91 6 (2006 Jun) 2145-2152
73. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
74. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
75. Bellone A., Vettorello M., Monari A., Cortellaro F., and Coen D. Noninvasive pressure support ventilation vs. continuous positive airway pressure in acute hypercapnic pulmonary edema. Intensive Care Med 31 (2005) 807-811
76. L'Her E., Duquesne F., Girou E., de Rosiere X.D., Le Conte P., Renault S., et al. Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients. Intensive Care Med 30 (2004) 882-888
77. Nava S., Carbone G., DiBattista N., Bellone A., Baiardi P., Cosentini R., et al. Noninvasive ventilation in cardiogenic pulmonary edema: a multicentered randomized trial. Am J Respir Crit Care Med 168 (2003) 1432-1437
78. Mehta S., Jay G.D., Woolard R.H., Hipona R.A., Connolly E.M., Cimini D.M., et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med 25 (1997) 620-628
79. Bellone A., Monari A., Cortellaro F., Vettorello M., Ariati S., and Coen D. Myocardial infarction rate in acute pulmonary edema: noninvasive pressure support ventilation versus continuous positive airway pressure. Crit Care Med 32 (2004) 1860-1865
80. Pang D., Keenan S.P., Cook D.J., and Sibbald W.J. The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest 114 (1998) 1185-1192
81. Masip J., Roque M., Sanchez B., Fernandez R., Subirana M., and Exposito J.A. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 294 (2005) 3124-3130
82. Peter J.V., Moran J.L., Phillips-Hughes J., Graham P., and Bersten A.D. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet 367 (2006) 1155-1163
83. Collins S.P., Mielniczuk L.M., Whittingham M.A., Boseley M.E., Schramm D.R., and Storrow A.B. The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review. Ann Emerg Med 48 (2006) 260-269
84. Gray A., Goodacre S., Newby D.E., Masson M., Sampson F., and Nicholl J. 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 359 (2008) 142-151
85. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
86. In: Shojania K.G., Duncan B.W., McDonald K.M., and Wachter R.M. (Eds). Making health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment no 43 (2001), Agency for Healthcare Research and Quality, Rockville, MD. AHRQ publication 01-E-058. Accessed at www.ahrq.gov/clinic/ptsafety/ on June 17, 2008
87. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius Study. Arch Intern Med 160 (2000) 3415-3420
88. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
89. Gheorghiade M., Zannad F., Sopko G., Klein L., Piña I.L., Konstam M.A., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
90. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., Boscardin W.J., ADHERE Scientific Advisory Committee, Study Group, and and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
91. Gheorghiade M., Abraham W.T., Albert N.M., Greenberg B.H., O'Connor C.M., She L., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
92. Belch J.J., Lowe G.D., Ward A.G., Forbes C.D., and Prentice C.R. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26 (1981) 115-117
93. Dahan R., Houlbert D., Caulin C., Cuzin E., Viltart C., Woler M., and Segrestaa J.M. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 16 (1986) 159-164
94. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 (1999) 793-800
95. Leizofrovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., and Goldhaber S.Z. PREVENT Medical Thromboprophylaxis Study Group. Circulation 110 (2004) 874-879
96. Mahe I., Bergmann J.F., d'Azemar P., Vaissie J.J., and Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double-blind study. Eur J Clin Pharmacol 61 (2005) 347-351
97. Cohen A.T., Davidson B.L., Gallus A.S., Lassen M.R., Prins M.H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 332 (2006) 325-329
98. Lederle F.A., Sacks J.M., Fiore L., Lendefeld C.S., Steinberg N., Peters R.W., et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 119 (2006) 54-59
99. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 347 (1996) 1357-1361
100. Dentali F., Douketis J.D., Lim W., and Crowther M. Combined aspirin-oral anticoagulant therapy compared with anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167 (2007) 117-124
101. Själander A., Jansson J.H., Bergqvist E.H., Carlberg B., and Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med 263 (2008) 52-60
102. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX Study. Blood Coagul Fibrinolysis 14 (2003) 341-346
103. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164 (2004) 963-968
104. Mismetti P., Laporte-Simitsidis S., Tardy B., Cucherat M., Buchmüller A., Juillar-Delsart D., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost 83 (2000) 14-19
105. Elkayam U., Bitar F., Akhter M.W., Khan S., Patrus S., and Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 9 (2004) 227-241
106. Parker J.D. Counterregulatory responses: sustained-release isosorbide- 5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol 28 (1996) 631-638
107. Dupuis J., Lalonde G., Lemieux R., and Rouleau J.L. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 16 (1990) 923-931
108. Elkayam U, Group VS. Superior hemodynamic effect of nesiritide (B- type natriuretic peptide) compared to high dose nitroglycerine (NTG) in patients with decompensated heart failure. In: NAIP Fifth Annual Meeting; 2002. p. 7.
109. Fung H.L., and Bauer J.A. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 8 (1994) 489-499
110. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
111. Mullens W., Abrahams Z., Francis G.S., Skouri H.N., Starling R.C., Young J.B., et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52 (2008) 200-207
112. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
113. Johnston G.D. Use of oganic nitrates in the treatment of heart failure. Fund Cardiovasc Pharm 6 (1999) 140-142
114. Abraham W.T., Lowes B.D., Ferguson D.A., Odom J., Kim J.K., Robertson A.D., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
115. Hobbs R.E., Miller L.W., Bott-Silverman C., James K.B., Rincon G., and Grossbard E.B. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 78 (1996) 896-901
116. Marcus L.S., Hart D., Packer M., Yushak M., Medina N., Danziger R.S., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94 (1996) 3184-3189
117. Mills R.M., LeJemtel T.H., Morton D.P., Liang C., Lang R., Silver M.A., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double- blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 34 (1999) 155-162
118. Colucci W.S., Elkayam U., Morton D.P., Abraham W.T., Bourge R.C., Johnson A.D., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343 (2000) 246-253
119. Wang D.J., Dowling T.C., Meadows D., AyalaT M.J., Minshall S., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
120. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
121. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
122. Vismara L.A., Leaman D.M., and Zelis R. The effects of morphine on venous tone in patients with acute pulmonary edema. Circulation 54 (1976) 335-337
123. Vasko J.S., Henney R.P., Oldham H.N., Brawley R.K., and Morrow A.G. Mechanisms of action of morphine in the treatment of experimental pulmonary edema. Am J Cardiol 18 (1966) 876-883
124. Sacchetti A., Ramoska E., Moakes M.E., McDermott P., and Moyer V. Effect of ED management of ICU use in acute pulmonary edema. Am J Emerg Med 17 (1999) 571-574
125. Hoffman J.R., and Reynolds S. Comparison of nitroglycerin, morphine and furosemide in treatment of presumed pre-hospital pulmonary edema. Chest 92 (1987) 586-593
126. Peacock W.F., Hollander J.E., Diercks D.B., Lopatin M., Fonarow G., and Emerman C.L. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 25 (2008) 205-209
127. Cotter G., Metzkor E., Kaluski E., Faigenberg Z., Miller R., Simovitz A., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
128. Levy P., Compton S., Welch R., Delgado G., Jennett A., Penugonda N., et al. Treatment of severe decompensated heart failure with high-dose intravenous nitrogycerin: a feasibility and outcome analysis. Ann Emerg Med 50 (2007) 144-152
129. Adams Jr. K.F., and Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 135 (1998) S204-S215
130. Gheorghiade M., Cody R.J., Francis G.S., McKenna W.J., Young J.B., and Bonow R.O. Current medical therapy for advanced heart failure. Heart Lung 29 (2000) 16-32
131. Cohn J.N., Franciosa J.A., Francis G.S., Archibald D., Tristani F., Fletcher R., et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306 (1982) 1129-1135
132. Packer M., Meller J., Medina N., Gorlin R., and Herman M.V. Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. N Engl J Med 301 (1979) 1193-1197
133. Bairn D.S., McDowell A.V., Cherniles J., Monrad E.S., Parker J.A., Edelson J., et al. Evaluation of a new bipyridine inotropic agent-mil- rinone-in patients with severe congestive heart failure. N Engl J Med 309 (1983) 748-756
134. Givertz M.M., Hare J.M., Loh E., Gauthier D.F., and Colucci W.S. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. JACC 28 (1996) 1775-1780
135. Monrad E.S., Bairn D.S., Smith H.S., and Lanoue A.S. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73 (1986) III168-III174
136. Baruch L., Patacsil P., Hameed A., Pina I., and Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 141 (2001) 266-273
137. Fonarow G.C., Adams Jr. K.F., Strausser B.P., and ADHERE Scientific Advisory Committee and Investigators. ADHERE (Acute Decompensate Heart Failure National Registry): Rationale, design, and subject population. J Card Fail 8 Suppl (2002) S49
138. Felker G.M., Benza R.L., Chandler A.B., Leimberger J.D., Cuffe M.S., Califf R.M., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
139. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C., Fonarow G.C., Hamilton M.A., Moriguchi J.D., et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96 (1997) 1165-1172
140. Shah M.R., O'Connor C.M., Sopko G., Hasselblad V., Califf R.M., and Stevenson L.W. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J 141 (2001) 528-535
141. Binanay C., Califf R.M., Hasselblad V., O'Connor C.M.E., Shah M.R., Sopko G., et al. Evaluation study of congestive heart failure and pulmonary artery Catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
142. Dalen J.E. The pulmonary artery catheter-friend, foe, or accomplice?. JAMA 286 (2001) 348-350
143. Rubenfeld G.D., McNamara-Aslin E., and Rubinson L. The pulmonary artery catheter, 1967-2007: rest in peace?. JAMA 298 (2007) 458-461
144. Wilkoff B.L., Cook J.R., Epstein A.E., Greene H.L., Hallstrom A.P., Hsia H., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123
145. Murphy N., Mockler M., Ryder M., Ledwidge M., and McDonald K. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail 13 (2007) 227-229